Gerhard Führwürth

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer's disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2--rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination was done at(More)
  • 1